Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02511405 |
| Title | A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE) |
| Acronym | GLOBE |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | No |
| Sponsors | Vascular Biogenics Ltd. operating as VBL Therapeutics |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA | ISR | CAN |